INTRODUCTION
The number of studies investigating the treatment of gastric cancer has grown rapidly in recent years. Findings from these studies have challenged established treatment norms and helped to introduce novel and more effective treatment paradigms for the management of gastric cancer. Broadly, these paradigms include the endoscopic management of localized gastric cancer in selected patients, [1] [2] [3] [4] [5] multimodality therapy for patients with locally advanced disease, [6] [7] [8] and the addition of molecular targeted agents to conventional chemotherapy regimens for patient subgroups with specific molecular aberrations. 9, 10 In the United States, gastric cancer is a major cause of cancer burden, with 28,000 cases diagnosed annually. 11, 12 Despite decreasing mortality, gastric cancer remains a highly lethal disease, with a 5-year survival rate of 30%. 13, 14 Therefore, translating effective evidence-based treatment options into general clinical practice has crucial implications for the outcomes of patients with gastric cancer.
The assimilation of new evidence into clinical practice is complex due to an array of factors. First, to our knowledge, there is a lack of conclusive practice guidelines regarding the treatment of gastric cancer owing to variability of the investigated therapies and infrequent head-to-head comparisons among these therapies. 9, 15, 16 Second, the generalizability of clinical trial findings to community practice historically has been poor. 17 Third, the delivery of novel treatment modalities depends on physicians' awareness and familiarity with new therapies as well as available system-level resources. 18, 19 To our knowledge to date, the management of gastric cancer in general practice in the United States has not been thoroughly investigated. In the current study, we described in comprehensive detail the current treatment of gastric cancer in the United States and examined its evolution over the past decade. By exposing current practice patterns and examining how these patterns have changed over time, the objective of the current study was to help improve understanding of the current treatment of gastric cancer in the United States, uncover potential driving factors of change, discover opportunities for improvement, and inform clinical trial design. In addition, providers caring for patients with gastric cancer will be able to use the findings of the current study to determine their position on the spectrum of the treatment of gastric cancer and to appreciate the trajectory of "standard" treatment for this patient population.
MATERIALS AND METHODS

Database and Study Population
After institutional review board approval, patients with International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) topography code C16 (gastric cancer) were abstracted from the National Cancer Data Base (NCDB) between 2006 and 2014. The NCDB is a joint program of the American College of Surgeons and the American Cancer Society. Approximately 70% of incident cancer cases in the United States are reported to the NCDB from >1500 national commission-accredited cancer programs. 20 We included only those patients with adenocarcinoma, specifically those with ICD-O-3 morphology codes 814, 821, 822, 825, 826, 831, 848, 849, and 857. Patients then were categorized according to their tumor location into cardia (ICD-O-3 code 16.0) and noncardia (ICD-O-3 codes 16.1-16.6 and 16.8). We abstracted patient data including demographics, comorbidity, income, and insurance type; tumor information such as clinical and pathological TNM stages, tumor extension, lymph node involvement, and grade; treatment details; and information regarding the reporting hospital including teaching status and the hospital's role in the care of the patient.
Patients diagnosed between 2006 and 2009 were staged in the NCDB using the sixth edition of the International Union Against Cancer/American Joint Committee on Cancer TNM staging manual. We revised their staging to reflect the stage categories of the seventh edition of the manual. A more detailed description of the changes implemented in the manual's seventh edition can be found elsewhere. [21] [22] [23] In the current study, we defined 3 stage groups: 1) early stage (TNM stage IA); 2) locally advanced stage (TNM stages IB, II, and III); and 3) metastatic stage (TNM stage IV). Within early-stage disease, we distinguished between T1a, tumor limited to the mucosa, and T1b, tumor invading the submucosa. We categorized the standard International Union Against Cancer/American Joint Committee on Cancer TNM stages into these groups for 2 reasons: 1) to maximize the mapping accuracy from the sixth edition onto the seventh edition of the TNM staging manual; and 2) to approximate the stage groups more closely to the current management approaches for patients with gastric cancer. Supporting Information Figure 1 demonstrates adequate stage mapping as is reflected in a smooth transition of the percentage of patients in each stage group, as well as the percentage of patients with missing staging information, over time. Patients with missing staging information (5238 patients; 5.6%) were excluded from this analysis. Their baseline characteristics and treatment information were compared with patients with available stage information and are listed in Supporting Information Table 1 .
Treatment data comprised resection type, receipt of systemic chemotherapy or chemoradiotherapy, and the sequence of delivery of chemotherapy and/or radiotherapy in relation to surgical resection. Curative-intent resections included endoscopic treatment, the overwhelming majority of which were endoscopic resection with or without ablative therapy, and surgical resections such as partial gastrectomy or total gastrectomy. Resections performed for palliation were not recorded as curative-intent resections. We divided treatment into 3 categories: 1) supportive care (no treatment); 2) curative therapy (resection only, resection with preoperative therapy, resection with postoperative therapy, and resection with perioperative therapy); and 3) palliative treatment (chemotherapy only and chemoradiotherapy only). The groups were mutually exclusive. We defined multimodality therapy as the combination of resection and chemotherapy or chemoradiotherapy. Within multimodality therapy, we distinguished among preoperative, postoperative, and perioperative chemotherapy and chemoradiotherapy.
Statistical Analysis
Hospital, patient, and tumor information were reported separately for patients with cardia and noncardia tumors. For each tumor location, stage-specific time trend analyses for treatment use were performed using a multivariable logistic regression. The period between 2006 and 2008 was the denoted reference period for the time trend analysis. We adjusted for patient age, sex, race/ethnicity, comorbidity, income, insurance type, and hospital teaching status. We evaluated trends within strata of hospital types, academic, and community hospitals. We also explored the impact of surgical and hospital volume on dominant temporal treatment trends by evaluating the interaction between volume and time. Because surgical and hospital volume were highly correlated (q 5 0.96), we used hospital volume only in our model.
Overall survival according to the period of diagnosis of gastric cancer was explored for each tumor location. Specifically, we compared overall survival at 3 years after diagnosis using the Kaplan were excluded from the survival analysis due to short and missing follow-up times, respectively. We also compared overall survival according to the period of diagnosis using a multivariable Cox proportional hazards model that included, in addition to time of diagnosis, variables recorded before the initiation of therapy: age, sex, race/ ethnicity, comorbidity, income, insurance type, and hospital teaching status. We also examined the potential impact of treatment trends on overall survival in a multivariable Cox proportional hazards model.
In the current study, we reported adjusted odds ratios (ORs) and adjusted hazards ratios (HRs) and their respective 95% confidence intervals (95% CIs). All statistical tests were 2-sided, and the significance level was set at .05. The analysis was implemented in Stata statistical software (version 14; StataCorp LLC, College Station, Texas).
RESULTS
Characteristics of the Study Population
In total, 89,098 patients with gastric adenocarcinoma were available for analysis: 40,413 (45%) had cardia and 48,685 (55%) had noncardia gastric cancer. The number of patients with gastric cancer increased over time (Table 1) . Greater than one-half of the patients were aged >65 years. It is interesting to note that cardia tumors predominantly affected non-Hispanic white males (79% male and 88% non-Hispanic white) whereas these demographics were found to be more balanced among patients with noncardia disease (57% male and 53% non-Hispanic white). The majority of patients presented with locally advanced disease; approximately one-third were found to have metastatic disease at the time of presentation. Among patients with noncardia cancer, the antrum was involved most frequently (36%).
The types of surgeries performed were broadly defined in the NCDB. For cardia tumors, approximately 59% of surgeries were labeled as gastrectomy with removal of a portion of the esophagus; the remaining surgeries were labeled as gastrectomy not otherwise specified or gastrectomy with removal of other organs. For patients with noncardia tumors, approximately 62% of the surgeries were labeled as partial/subtotal gastrectomy, 16% as near total/total gastrectomy, and the remainder as gastrectomy not otherwise specified and gastrectomy with removal of the esophagus or other organs. In these surgeries, the number of lymph nodes examined increased over time. Among patients with cardia tumors, the mean number of lymph nodes examined increased from 14. 
Treatment of Cardia Gastric Cancer
Treatment use among patients with cardia disease varied across disease stage. The majority of patients with earlystage cardia disease underwent a resection (Table 2) . Among those, 44% had an endoscopic resection, whereas the remaining patients underwent a gastrectomy. Patients with T1aN0M0 disease were more likely to undergo an endoscopic procedure compared with patients with T1bN0M0 disease (Fig. 1 ) (see Supporting Information The majority of patients with cardia tumors presented with locally advanced disease (58%) and received multimodality therapy in the form of preoperative therapy and resection ( Table 2 ). The use of multimodality therapy for locally advanced cardia disease increased during the study period (2013-2014: OR, 1.35, 95% CI, 1.25-1.47) ( Table 3) (Fig. 2 ) (see Supporting Information Table 3 ). This trend was predominantly related to an increased use of preoperative chemoradiotherapy (2013-2014: OR, 3.09, 95% CI, 2.80-3.41). The delivery of preoperative therapy marginally varied by hospital volume (OR for the volume-time interaction term, 0.96; P 5 .03). The difference in preoperative therapy between community and academic hospitals was 6% (30% vs (Fig. 3 ) (see Supporting Information Table 4 ).
Treatment of Noncardia Gastric Cancer
Patients with noncardia gastric cancer had a distinctively different pattern of treatment use compared with patients 
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Cancer March 15, 2018 with cardia disease. The majority of patients with earlystage noncardia tumors underwent resection only ( Table  2 ). Unlike patients with cardia tumors, <13% of patients with noncardia tumors underwent an endoscopic resection; the majority were treated with a gastrectomy. However, the use of endoscopic resection among resected patients with early-stage noncardia disease increased over the study period (2013-2014: OR, 2.38, 95% CI, 1.87-3.03) ( Table 3 ). In 2014, approximately 23% and 10%, respectively, of patients with resected T1aN0M0 and T1bN0M0 noncardia disease underwent an endoscopic resection ( Fig. 1 ) (see Supporting Information Table 2 ).
Among patients with locally advanced noncardia tumors, resection alone (34%) and resection plus postoperative therapy (34%) were the most commonly used treatment modalities (Table 2) . Only 13% of patients who underwent tumor resection received preoperative or perioperative therapy. Nevertheless, the use of preoperative and perioperative therapy increased over time (2013) (2014) (Fig. 2 ) (see Supporting Information Table 3 ). It is interesting to note that the delivery of preoperative therapy increased at a slightly faster rate in academic hospitals compared with community hospitals (8% and 3%, respectively, in 2006-2008 vs 19% and 12%, respectively, in 2013-2014) . Moreover, preoperative therapy varied by hospital volume (OR for the volume-time interaction term, 0.92; P<.01).
In patients with metastatic noncardia cancers, approximately 40% did not receive any treatment (Table 2) . We noted a small increase in the use of chemotherapy or chemoradiotherapy only over the study period (2013-2014: OR, 1.23, 95% CI, 1.12-1.34) ( Table 3) (Fig. 3 ) (see Supporting Information Table 4 ).
Overall Survival
Overall survival at 3 years for all patients with gastric cancer improved slightly between 2006 and 2012 at 29% (95% CI, 28%-30%) and 33% (95% CI, 32%-34%), respectively. Similar 3-year survival trends were noted within stage-specific and location-specific strata. The 3-year overall survival rates for the period from 2011 through 2012 versus 2006 through 2008 were as follows according to tumor stage and location: 70% versus 65% for early cardia (adjusted HR, 0.81; 95% CI, 0.69-0.96), 40% versus 36% for locally advanced cardia (adjusted HR, 0.88; 95% CI, 0.84-0.92), 8% versus 6% for metastatic cardia (adjusted HR, 0.90; 95% CI, 0.86-0.95), 64% versus 65% for early noncardia (adjusted HR, 1.00; 95% CI, 0.89-1.12), 45% versus 39% for locally advanced noncardia (adjusted HR, 0.87; 95% CI, 0.83-0.92), and 8% versus 5% for metastatic noncardia (adjusted HR, 0.86, 95% CI, 0.82-0.90).
DISCUSSION
In the current study, we explored recent treatment use and survival trends in general clinical practice for patients with gastric adenocarcinoma in the United States. Shifts in treatment options were distinct for cardia and noncardia tumors, reflecting an advance in the understanding of heterogeneity within gastric cancer. Specifically, endoscopic resection was increasingly performed for patients with early-stage cardia tumors and the preoperative delivery of chemoradiotherapy and chemotherapy increased dramatically in lieu of postoperative therapy for individuals with locally advanced cardia and noncardia disease, respectively. The treatment of metastatic disease remained stable and significantly underused over the study period.
Within the past decade, the current study findings highlight a shift in the treatment of early-stage cardia tumors from surgical resection to endoscopic treatment. In 2014, greater than two-thirds of patients with T1aN0 cardia tumors underwent endoscopic resection compared with fewer than one-third of patients in 2006. This increase in endoscopic treatment did not impact overall survival (HR for the trend of endoscopic treatment overtime, 0.96; 95% CI, 0.89-1.02).The increase in the endoscopic treatment of T1N0 cardia tumors mirrors a similar trend in the management of localized distal esophageal adenocarcinoma. 24 Admittedly, the distinction between true cardia tumors and distal esophageal disease represents a challenge given that both tumors often involve the gastroesophageal junction and, recently, both tumors have been grouped and managed similarly. 16, 23, 25 The inclination toward the increased use of endoscopic options is expected because of several factors: 1) multiple studies demonstrating comparable long-term survival with endoscopic management and promising recurrence rates; 2) low procedural morbidity compared with esophagectomy; and 3) increased familiarity with endoscopic techniques. 5, [26] [27] [28] We also noted a commensurate increase in the endoscopic treatment of patients with T1bN0 cardia tumors. Currently, National Comprehensive Cancer Network guidelines support endoscopic resection for patients with intramucosal lesions (T1aN0). Surgical resection is favored for patients with lesions that extend beyond the mucosa (T1bN0), 25, 29 because submucosal disease is associated with 24% lymph node metastasis. 30 Nevertheless, approximately 43% of patients with T1bN0 cardia tumor in the current study underwent endoscopic resection in 2014, a 4-fold increase compared with 2006.
The increased use of preoperative chemoradiotherapy for patients with cardia tumors and preoperative chemotherapy for patients with noncardia tumors was a dominant trend among patients with locally advanced disease. Compared with postoperative therapy, preoperative therapy has several advantages, including a greater likelihood of completing treatment, a rapid improvement in tumor-related symptoms, the potential to downstage tumors, and the ability to assess response to preoperative therapy. In addition, patients with unfavorable tumor biology or unrecognized metastatic disease are spared a potentially morbid surgical procedure. In the current study, the increased delivery of preoperative therapy was associated with improved overall survival (cardia: HR for the temporal Preoperative therapy has been firmly established as the optimal treatment approach for locally advanced cardia gastric cancer according to findings from multiple clinical trials. [31] [32] [33] [34] [35] [36] [37] [38] [39] Both perioperative chemotherapy and preoperative chemoradiotherapy have been shown to improve survival compared with surgery alone. 38, 39 The shift from upfront resection to preoperative therapy followed by resection for gastroesophageal tumors including the gastric cardia began in the late 1990s. 40 The findings of the current study demonstrate that approximately 87% of patients with cardia gastric cancer undergoing multimodality therapy in 2014 received chemotherapy or chemoradiotherapy prior to resection.
In patients with noncardia gastric cancer, the receipt of preoperative therapy is a more recent trend. Over the entire study period, postoperative chemoradiotherapy was the predominant treatment modality among patients with locally advanced noncardia disease who received multimodality therapy. This treatment regimen followed publication of the Intergroup 0116 (INT 0116) trial, which demonstrated a marked survival difference in patients with gastric cancer randomized to surgery plus postoperative chemoradiotherapy compared with those undergoing surgery alone. 41 Five years later, in 2006, the landmark Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial demonstrated improved survival among patients with locally advanced, and predominantly noncardia, gastric adenocarcinoma who were randomized to receive perioperative chemotherapy compared with surgery alone. 42 It is around that period when preoperative and perioperative therapy for noncardia gastric cancer expanded 43 (see Supporting Information Table  5 for a list of recently reported key clinical trials evaluating the treatment of gastric cancer).
In the current study, patients with locally advanced noncardia tumors more frequently received preoperative chemotherapy (23% in 2014) than perioperative chemotherapy (13%). The NCDB does not indicate whether patients were unable to complete perioperative treatment and only the preoperative component was administered. In what to our knowledge are the 2 major randomized control trials that investigated perioperative chemotherapy for patients with locally advanced gastric cancer, 35% to 50% of patients who completed preoperative chemotherapy did not receive the postoperative chemotherapy component. 38, 42 Another possible explanation may be related to a trend toward delivering all chemotherapy cycles preoperatively instead of adhering to the perioperative chemotherapy delivery protocols used in the MAGIC trial. 44 Treatment delivery to patients with metastatic disease persisted at alarmingly low rates over the study period. This underuse of treatment was concerning at academic hospitals, and even more so at community hospitals (delivery of chemo[radio]therapy: 51% vs 45%, respectively, in 2006-2008 vs 47% vs 53%, respectively, in 2013-2014). Although the treatment of metastatic disease is palliative, cytotoxic chemotherapy still can relieve cancer-related symptoms, improve quality of life, and prolong survival. More importantly, patients with advanced unresectable disease as well as metastatic disease should be encouraged to enroll into ongoing clinical trials.
The findings of the current study must be interpreted in the light of the following limitations. First, the NCDB collects data only from accredited member facilities. Second, the large number of patients not receiving treatment for early-stage tumors may be related to the underreporting of endoscopic treatment. If a significant percentage of small tumors are completely excised during a diagnostic procedure, these patients may not be registered in the NCDB as having undergone a definitive resection. Another source of underreporting of treatment may be related to the fact that the NCDB does not consolidate patient records from different facilities; it is expected that each facility includes care delivered at other hospitals in their reports. 45 Despite the concerns related to the percentage of patients with early-stage disease treated, we believe the trends in treatment use are real. It is less likely that the trends reflect potentially improved accuracy of abstraction of treatment information because our treatment trends mirror those reported in other databases, and the percentage of patients reported as not having received treatment is comparable across the study years. Last, the chemotherapy or chemoradiotherapy regimens are not specified in the NCDB and therefore we were not able to comment regarding the specific regimens used.
The treatment of gastric adenocarcinoma in general practice in the United States has been evolving rapidly over the past decade. Despite apparent challenges in translating trial findings into general clinical practice, the results of the current study indicate a rapid adoption of evidence-based treatments: the endoscopic management of early-stage disease expanded markedly, and the preoperative delivery of therapy is increasingly favored among patients with locally advanced disease in lieu of postoperative therapy. The treatment of metastatic disease remains underused without significant shifts in trend noted. Ideally, those patients would enroll in ongoing trials exploring novel treatment regimens, but in the meantime, patients with metastatic gastric cancer should be informed of the current evidence supporting the potential benefit (and risks) of chemotherapy in improving quality of life and survival.
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